Dear colleagues,
Since 2008, we continue to collect data to establish a comprehensive, quantitative map of patients being treated in Europe with cellular and engineered tissue therapies (i.e. any clinical treatment based on living cells excluding donor lymphocyte infusions, CAR-T cells, or hematopoietic stem cells for hematological reconstitution). The survey is coordinated by the ISCT and TERMIS-EU and supported by further international organizations, namely EBMT, IFATS, ICRS, and the ON foundation.
If, in 2020 and/or 2021, you treated patients with cellular or engineered tissue therapies in Europe or a non-EU EBMT associated country (Algeria, Iran, Israel, Jordan, Lebanon, Nigeria, Saudi Arabia, South Africa or Tunisia) please complete the attached survey forms for the respective year and send it no later than February 28th 2022 to Dr. Max Gay by Email: MaxHPG@outlook.com. Your data will be used to generate a report (last edition report was recently published in Tissue Engineering-Part A), that this year will be submitted to the journal Cytotherapy. In addition, your name will be listed among the participating teams to acknowledge your contribution to gain transparency in this rapidly evolving field.
If you have practiced such therapies in the previous years or have them in preparation for the coming years but did not perform any cell-based treatment in 2020 and 2021, please note this in the survey in the designated field and enter your group information. This way we can also ascertain the variety of teams capable of performing such therapies and you would also be acknowledged in the report.
Please be aware that we have changed the survey template from that of previous years, in an attempt to simplify reporting. If you have any question or suggestion for improvement, please contact Dr. Max Gay at the previously mentioned Email address.
We strive to make the results available to the scientific community earlier than in past editions and to achieve this we ask for your compliance to the indicated deadline.
Finally, if you know of any group that is performing such therapies please forward this message to them and encourage them to participate. This will help us to have a more thorough representation of the European landscape in the survey.
Thank you for the support to this program!
Prof. Ivan Martin PhD
Department of Biomedicine
University Hospital Basel, CH
Background to the Survey
The survey is designed to establish a comprehensive, quantitative map of patients being treated in Europe with cellular and engineered tissue therapies. Now in its 8th year, it is supported by the following 5 international societies
- the Tissue Engineering & Regenerative Medicine Society, European Chapter (TERMIS-EU),
- the International Society for Cell & Gene Therapy, Europe Region (ISCT-Europe),
- the International Cartilage Repair Society, European Section (ICRS),
- the European group for Blood and Marrow Transplantation (EBMT),
- the International Federation for Adipose Therapeutics and Science (IFATS),
- the Orthoregeneration Network (ON)
Enclosures
Present Survey Materials
Survey Instructions for Reporting
Click here to download the following submission documents:
- Cellular Therapy and Regenerative Medicine Survey 2020 (Excel)
- Cellular Therapy and Regenerative Medicine Survey 2021 (Excel)
Past Survey Reports
The Survey on Cellular and Engineered Tissue Therapies in Europe 2008
The Survey on Cellular and Engineered Tissue Therapies in Europe 2009
The Survey on Cellular and Engineered Tissue Therapies in Europe 2010
The Survey on Cellular and Engineered Tissue Therapies in Europe 2011
The Survey on Cellular and Engineered Tissue Therapies in Europe 2012
The Survey on Cellular and Engineered Tissue Therapies in Europe 2013
The Survey on Cellular and Engineered Tissue Therapies in Europe and neighboring Eurasian countries in 2014 and 2015
The Survey on Cellular and Tissue-Engineered Therapies in Europe in 2016 and 2017